JP2011162558A5 - - Google Patents

Download PDF

Info

Publication number
JP2011162558A5
JP2011162558A5 JP2011110047A JP2011110047A JP2011162558A5 JP 2011162558 A5 JP2011162558 A5 JP 2011162558A5 JP 2011110047 A JP2011110047 A JP 2011110047A JP 2011110047 A JP2011110047 A JP 2011110047A JP 2011162558 A5 JP2011162558 A5 JP 2011162558A5
Authority
JP
Japan
Prior art keywords
tissue
galnac4st
c6st
test compound
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011110047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011162558A (ja
JP5481426B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2011110047A priority Critical patent/JP5481426B2/ja
Priority claimed from JP2011110047A external-priority patent/JP5481426B2/ja
Publication of JP2011162558A publication Critical patent/JP2011162558A/ja
Publication of JP2011162558A5 publication Critical patent/JP2011162558A5/ja
Application granted granted Critical
Publication of JP5481426B2 publication Critical patent/JP5481426B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011110047A 2007-12-27 2011-05-17 糖鎖関連遺伝子、およびその利用 Active JP5481426B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011110047A JP5481426B2 (ja) 2007-12-27 2011-05-17 糖鎖関連遺伝子、およびその利用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007336518 2007-12-27
JP2007336518 2007-12-27
JP2011110047A JP5481426B2 (ja) 2007-12-27 2011-05-17 糖鎖関連遺伝子、およびその利用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010173610A Division JP4751956B2 (ja) 2007-12-27 2010-08-02 糖鎖関連遺伝子、およびその利用

Publications (3)

Publication Number Publication Date
JP2011162558A JP2011162558A (ja) 2011-08-25
JP2011162558A5 true JP2011162558A5 (https=) 2013-02-14
JP5481426B2 JP5481426B2 (ja) 2014-04-23

Family

ID=40823968

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009547912A Active JP4585611B2 (ja) 2007-12-27 2008-12-26 糖鎖関連遺伝子、およびその利用
JP2010173610A Active JP4751956B2 (ja) 2007-12-27 2010-08-02 糖鎖関連遺伝子、およびその利用
JP2011110047A Active JP5481426B2 (ja) 2007-12-27 2011-05-17 糖鎖関連遺伝子、およびその利用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2009547912A Active JP4585611B2 (ja) 2007-12-27 2008-12-26 糖鎖関連遺伝子、およびその利用
JP2010173610A Active JP4751956B2 (ja) 2007-12-27 2010-08-02 糖鎖関連遺伝子、およびその利用

Country Status (7)

Country Link
US (6) US20110027248A1 (https=)
EP (4) EP2238987A4 (https=)
JP (3) JP4585611B2 (https=)
KR (6) KR102244872B1 (https=)
CN (2) CN101965196A (https=)
SG (2) SG10201402793PA (https=)
WO (1) WO2009084232A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3711755A1 (en) * 2007-06-29 2020-09-23 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Method of fixing and expressing physiologically active substance
KR20120039742A (ko) * 2009-07-31 2012-04-25 가부시끼가이샤 스텔릭 사이세이 이카가꾸 겐뀨쇼 지방성 간염-간암 모델 동물
KR102059054B1 (ko) 2011-11-18 2019-12-24 닛토덴코 가부시키가이샤 장 섬유증 치료제
EP2876162A4 (en) * 2012-07-17 2016-03-16 Stelic Institute&Co MUCOSA CURE PROMOTER
DK2992098T3 (da) * 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
JP6302183B2 (ja) * 2013-07-12 2018-03-28 株式会社エンザミン研究所 アディポサイトカイン産生バランス調整剤及び脂肪組織の炎症・酸化ストレス抑制剤並びに脂肪組織のマクロファージ浸潤抑制剤
EP3265567B1 (en) 2015-03-02 2020-07-29 Conagen Inc. Regulatory elements from labyrinthulomycetes microorganisms
US10646579B2 (en) 2015-11-04 2020-05-12 Tme Therapeutics Inc. Complex comprising RNAi molecule and N-acetylated chitosan
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
JP7129912B2 (ja) 2016-12-07 2022-09-02 株式会社ステリック再生医科学研究所 慢性疾患の治療及び予防用医薬組成物
CA3054159A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
EP3762485A4 (en) * 2018-03-05 2021-12-08 Conagen Inc. ORGANISMS AND METHOD FOR MANUFACTURING GLYCOMOLECULES WITH LOW SULFATION
CN109897812B (zh) * 2019-03-19 2021-09-03 江南大学 一种表达软骨素4-硫酸转移酶基因的重组菌及其应用
US12527812B2 (en) 2019-05-08 2026-01-20 Tme Therapeutics Inc. Esophageal stricture suppressing agent
CN116254296A (zh) * 2023-03-27 2023-06-13 中国科学院微生物研究所 利用昆虫细胞杆状病毒表达系统表达硫酸软骨素修饰酶的方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4571242B2 (ja) * 1996-07-24 2010-10-27 生化学工業株式会社 ヒト由来のグリコサミノグリカンスルホトランスフェラーゼのポリペプチド及びそれをコードするｄｎａ
WO1998046258A2 (en) * 1997-04-11 1998-10-22 Beth Israel Deaconess Medical Center, Inc. Use of chondroitinase in the manufacture of a medicament in the treatment and prevention of mucoid secretions
CA2393186A1 (en) * 1999-12-02 2001-06-07 Ibex Technologies, Inc. Attenuation of fibroblast proliferation
EP1839671A3 (en) * 1999-12-02 2007-10-31 BioMarin Pharmaceutical Inc. Attenuation of fibroblast proliferation
US6713274B2 (en) * 2002-05-13 2004-03-30 The Regents Of The University Of California Method for identifying modulators of sulfotransferase activity
US20060128659A1 (en) * 2002-07-10 2006-06-15 Osami Habuchi Sulfotransferase inhibitors
EP1734970B1 (en) * 2004-03-12 2014-12-31 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
WO2007049361A1 (ja) * 2005-10-27 2007-05-03 Stelic Corp. 肝線維化抑制剤
US20090202515A1 (en) * 2006-09-08 2009-08-13 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Agents for suppressing neural fibrotic degeneration
JP2009286695A (ja) * 2006-09-08 2009-12-10 Stelic Institute Of Regenerative Medicine 眼線維性血管新生抑制剤
EP3711755A1 (en) * 2007-06-29 2020-09-23 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Method of fixing and expressing physiologically active substance

Similar Documents

Publication Publication Date Title
JP2011162558A5 (https=)
JP2011037847A5 (https=)
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
AU2018260825A1 (en) Compositions and Methods for Lowering Levels of High-Sensitivity (hs-CRP) in a Subject
HK1199068A1 (en) Identification of gene expression profile as a predictive biomarker for lkb1 status
JP2012050449A5 (https=)
EA202091568A1 (ru) Ингибиторы глюкозилцерамид-синтазы
BR112014015202A8 (pt) processo para a melhor separação de uma solução orgânica hidrófoba de um meio de cultura aquoso
EA201201113A1 (ru) Способы и соединения для роста мышц
WO2015048793A3 (en) Nucleic acid biomarker and use thereof
JP2009178558A5 (https=)
EA201401353A1 (ru) Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк)
WO2010019914A3 (en) Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
JP2016528914A5 (https=)
NZ624708A (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
JP2013527772A5 (https=)
PH12014502282A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
Huang et al. Circulating cell-free DNA levels correlate with postresuscitation survival rates in out-of-hospital cardiac arrest patients
WO2013141705A3 (en) Means and methods for response prediction of hepatitis b treatment
WO2008008487A3 (en) Gene expression profiling for identification, monitoring and treatment of multiple sclerosis
WO2012078648A3 (en) Novel method of cancer diagnosis and prognosis and prediction of response to therapy
NZ624714A (en) Methods for treating gout in patient subpopulations
RU2009145864A (ru) Способ прогнозирования дизадаптации сердечной деятельности у детей, перенесших кардиохирургическую коррекцию врожденного порока сердца
PH12019500738A1 (en) Methods of preserving the biological activity of ribonucleic acids
RU2017139718A (ru) Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост для таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток